News from genocea biosciences inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 18, 2013, 08:30 ET

Genocea Biosciences Appoints Katrine Bosley As Chairman Of The Board Of Directors; Vaccine Industry Leader George Siber, M.D. To Serve As Executive Director And Head Of Scientific Advisory Board

 Genocea Biosciences, Inc., a clinical-stage company developing novel T cell vaccines, announced today that Katrine Bosley, who previously...

Sep 12, 2013, 17:00 ET

Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013

 Genocea Biosciences Inc., a clinical-stage biopharmaceutical company developing T cell vaccines to prevent and treat infectious diseases,...

Aug 28, 2013, 08:00 ET

Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013

 Genocea Biosciences Inc., a clinical-stage company developing T cell vaccines to prevent and treat infectious diseases, announced today that...

Mar 18, 2013, 07:30 ET

Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2

Genocea Biosciences Inc., a clinical-stage company pioneering novel T cell vaccines, announced today the publication of new data to support...

Mar 12, 2013, 08:00 ET

Industry Veteran Katrine Bosley Joins Genocea Biosciences' Board Of Directors

 Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has added Katrine Bosley, a...

Oct 10, 2012, 07:00 ET

Genocea Closes $30 Million in Series C Financing

 Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge